Canaccord Genuity Welcomes Kyle Mikson, Director, Equity Research8th July 2021
Canaccord Genuity is pleased to welcome Kyle Mikson, Director, Senior Equity Research Analyst covering the Life Science Tools and Diagnostics sector. Kyle will focus on expanding our firm’s footprint on important emerging growth trends such as genomics, molecular diagnostics, liquid biopsy, proteomics and spatial biology.
Kyle joins us after several years leading successful equity research efforts in the Life Science Tools and Diagnostics sector, and he also has prior industry experience in finance roles at Express Scripts, a pharmaceutical benefit management company. Kyle holds a BS degree in Biomedical Engineering from Case Western Reserve University and is a CFA Charter holder.
Kyle joining Canaccord Genuity underscores the firm’s commitment to Life Sciences and Healthcare, which in addition to the life science tools & diagnostics sector, includes in-depth coverage of biotechnology, medical technology, healthcare services, and healthcare IT. We look forward to building on the success and accomplishments we have enjoyed in these segments.
How can we help?
If you would like to find out more about Canaccord Genuity or any of our services, please get in touch.